Clinical trials
Pancreatic Cancer, Adult clinical trials
Below are recruiting pancreatic cancer, adult clinical trials, each written for real people, not researchers. We’re tracking 108 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06598007RecruitingPhase 1/Phase 2
Studying CT3001 for advanced solid tumors
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
Houston, TexasAges 18 years+ - NCT06801899Recruiting
Total vs. partial Whipple for high-risk pancreatic cancer
This trial compares removing the entire pancreas (total pancreatectomy) versus removing only the head (standard Whipple) for certain cancers of the pancreas, bile duct, or ampulla. It is for people whose surgeon thinks the pancreas connection after surgery is likely to leak, which can cause serious complications.
MünsterAges 18 years+ - NCT07407231Recruiting
Chemo and radiation for advanced inoperable pancreatic cancer
This trial tests a combined treatment of chemotherapy followed by a precise type of radiation therapy (SBRT) for people with pancreatic cancer that cannot be surgically removed. It is designed for those who have not yet started treatment for locally advanced disease.
LjubljanaAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT07536841Recruiting
Testing New Criteria for Autoimmune Pancreas Inflammation
This study validates a new diagnostic tool (Odesa Criteria 2026) to help doctors accurately identify autoimmune pancreatitis—a rare condition where the body attacks the pancreas. If you're being evaluated for possible pancreas inflammation, this trial may help confirm whether you have this specific type.
OdesaAges 18 years+ - NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT07243262Recruiting
Breath test for pancreatic cancer detection
This trial tests whether a simple breath test can help detect pancreatic cancer earlier. If you have been referred for possible pancreatic cancer, you may be able to take part.
LondonAges 18 years+ - NCT07552467Recruiting
PET Imaging Scan for Detecting Cancer Using New Radioactive Tracer
This study tests a new type of imaging scan (PET/CT or PET/MR) that uses a radioactive tracer to help doctors better detect and diagnose various cancers. The scan targets a specific protein found in tumors, which may help identify cancer more accurately than standard imaging.
Wuhan, HubeiAges 18 years+ - NCT07307664Recruiting
Increasing genetic testing for cancer patients
This trial aims to increase the use of genetic testing (germline testing) among cancer patients by working with healthcare providers like oncologists and nurses. If you are an oncology care team member treating adults with breast, pancreatic, or colorectal cancer, this study may be for you.
Los Angeles, CaliforniaAges Any age - NCT07619391Recruiting
MyCap App: Tracking Treatment Time Burden in Pancreatic Cancer
This study asks pancreatic cancer patients to use a smartphone app called MyCap that tracks how much time their cancer treatment takes—like travel to appointments, time in the clinic, and side effects. Researchers want to understand the full burden of treatment to help doctors and future patients plan better.
Columbus, OhioAges 18 years+ - NCT04575363Recruiting
Testing a blood marker to predict pancreatic cancer outcomes
This study looks at a test called RPSA to see if it can help predict how pancreatic cancer may turn out. It includes people being treated at Reims University Hospital for pancreatic tumors that can be removed (or may become removable).
ReimsAges 18 years+ - NCT05727020Recruiting
Breath test study for pancreatic cancer and related conditions
This study checks whether breathing out certain chemicals (volatile organic compounds) can help identify pancreatic ductal adenocarcinoma (pancreatic cancer) or related pancreas problems. You may qualify if you’re an adult with suspected/confirmed pancreatic conditions and can safely take part in breath testing or surgery-related tissue collection.
LondonAges 18 years+ - NCT07610798RecruitingPhase 1/Phase 2
Testing INV-8989 for Advanced Cancers With KRAS G12D Mutation
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT03823144Recruiting
Imaging small live tumor details during surgery
This study uses a special camera to look at solid tumors from inside the body during an operation. It tests whether “live” tumor imaging (using a medicine called fluorescein) can be safely performed in people with certain solid cancers.
Jacksonville, FloridaAges 18 years+ - NCT05117723Recruiting
IPMN cyst database to help predict pancreatic cancer risk
This study collects information from people who have an IPMN cyst in the pancreas to help predict who may be at higher risk of pancreatic cancer. It may help your care team estimate risk and plan follow-up more effectively.
Fitzroy, VictoriaAges 18–90 - NCT06287749Recruiting
Liquid biopsy for monitoring pancreatic cancer after surgery
This trial is testing a blood test (liquid biopsy) to look for tiny traces of cancer DNA after surgery for pancreatic cancer. It may help doctors understand if the cancer is likely to come back.
Montpellier, HéraultAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07094204RecruitingPhase 1
A study of ASP5834 for adults with solid tumors and KRAS mutations
This trial is testing a new drug called ASP5834 for people with advanced solid tumors that have a specific change in the KRAS gene. The study will find the best dose and see if it helps shrink tumors.
Santa Monica, CaliforniaAges 18 years+ - NCT06319755Recruiting
Gut bacteria after Whipple surgery
This study looks at gut bacteria in people who had Whipple surgery for pancreatic cancer and in healthy volunteers. It aims to understand how the microbiome changes after surgery.
Camperdown, New South WalesAges 18 years+ - NCT06843629Recruiting
PET scan test for MSLN in cancer patients
This study uses a special PET scan to look for a protein called MSLN in certain cancers like pancreatic, ovarian, and lung cancer. It aims to see if this imaging method can help doctors understand your tumor better.
Wuhan, HubeiAges 18–65 - NCT05346536Recruiting
Test blood test for a specific type of pancreatic cancer cell
This trial looks for pancreatic cancer markers in a blood sample (“liquid biopsy”), focusing on cells that show a certain protein (AXL). It may help doctors detect and better track advanced pancreatic cancer before or during first-line treatment.
MontpellierAges 18 years+
Hear when a new Pancreatic Cancer, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic cancer, adult?
- Yes. Clin2 currently lists 108 recruiting pancreatic cancer, adult studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic cancer, adult trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic cancer, adult trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.